ahk-cu 100mg | 99%+ Purity | Lyophilised Powder AHK-Cu (100mg) | Alphacore

General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data

Microdosing is a drug administration method involving significantly lower doses than are typically used for therapeutic effects

5-Amino-1MQs ability to shift the bodys energy utilization from storage to active fat-burning helps prevent the buildup of harmful fat, reducing these effects

Doctors might change this based on how well the patient is doing

The example math below uses 3.0 mL of bacteriostatic water per 50 mg vial, which gives roughly 16.7 mg/mL of compound in solution